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Lasers in Urology
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Purpose: Intravesical protrusion of the prostate (IPP) can affect voiding. We evaluated 
the improvement in lower urinary tract symptoms and patient satisfaction after laser 
prostate photovaporization in benign prostatic hyperplasia (BPH) patients with or 
without IPP.
Materials and Methods: This prospective study included 134 patients who underwent 
GreenLight HPS laser photoselective vaporization prostatectomy (PVP) between 
January 2010 and July 2011 patient. Preoperative IPP was evaluated by using the ret-
roflexed view from flexible cystoscopy. evaluation included complete medical history, 
International Prostate Symptom Scores (IPSS), maximum flow rate (Qmax), postvoid 
residual (PVR), serum prostate-specific antigen (PSA), and transrectal ultrasonogram. 
Changes from baseline in Qmax, PVR, total IPSS, and IPSS subscores (voiding and stor-
age) were analyzed at postoperative months 1, 3, and 6.
Results: The patients’ mean age was 66.6±7.8 years. Mean serum PSA and prostate 
volume were 1.7±1.5 ng/mL and 42.9±16.7 g, respectively. No significant differences 
existed between the IPP and no IPP groups in preoperative prostate volume, total IPSS, 
PSA, or lasing time and energy. The mean follow-up duration was 6.2±1.9 months. IPP 
patients showed significant improvements in total IPSS and voiding subscores at 
months 1 and 3. Improvements in the quality of life score and storage subscore were 
not significantly different between the groups. Qmax was significantly improved at 6 
months postoperatively in the IPP group versus the no IPP group.
Conclusions: Among patients who underwent PVP for BPH, the IPP group showed more 
symptom improvement, especially in voiding symptoms, than did the no IPP group. 
Preoperative cystoscopy is helpful for evaluating IPP and for anticipating postoperative 
outcome.
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INTRODUCTION
Recent studies have concentrated on prostatic config-
uration rather than overall prostatic volume in the etiology 
of bladder outlet obstruction (BOO). Several authors con-
sider intravesical prostatic protrusion (IPP) to be a useful 
parameter in predicting BOO [1,2]. A higher IPP grade is 
associated with a higher risk of clinical progression in be-
nign prostatic hyperplasia (BPH). Thus, resolving IPP may 
improve the outcome of BPH management [3]. Even if IPP 
is a useful predictor of clinical progression in BPH, IPP 
measured by abdominal ultrasound (US) is operator-de-
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pendent, which limits its broad reproducibility [4]. Flexible 
cystoscopy is a more invasive technique than is abdominal 
US; however, cystoscopy can more precisely evaluate ure-
thral abnormalities, including bladder outlet compression. 
Therefore, we assessed the effectiveness of laser PVP on 
BPH that was evaluated by flexible cystoscopy and com-
pared clinical outcomes between BPH patients with IPP 
and those without IPP. 
MATERIALS AND METHODS
1. Patients
Our university’s Institutional Review Board approved this 
study. We enrolled 134 patients who underwent Green-
Light HPS laser photoselective vaporization prostatec-
tomy (PVP) at our institution between January 2010 and 
July 2011. The urethral and bladder neck anatomical con-
figurations of the patients were evaluated by flexible cysto-
scopy before surgery. Patients received a minimum of 3 
months of medical therapy before surgery and were not sat-
isfied with their medical therapy. Patients received an ini-
tial baseline evaluation that included a transrectal ultra-
sound (TRUS) and had maximum flow rate (Qmax), post-
void residual (PVR) volume, and serum prostate-specific 
antigen (PSA) levels measured. Patients were also ad-
ministered the International Prostate Symptom Score 
(IPSS) questionnaire. A lack of satisfaction with medical 
therapy was defined as changes from baseline in the IPSS 
and quality of life (QoL) scores of less than 3 and 1 points, 
respectively. We used the GreenLight HPS 120 W laser 
(American Medical Systems, Minnetonka, MN, USA) to 
perform the PVP procedure. Postoperatively, all patients 
were assessed with the IPSS and for Qmax and PVR at 1, 
3, and 6 months after the operation. Exclusion criteria were 
current use of medications known to affect bladder function 
(i.e., anticholinergics), severe symptoms necessitating im-
mediate medical or surgical intervention, complications 
potentially related to lower urinary tract symptoms (e.g., 
PSA level over 10 ng/mL, residual volumes over 200 mL, 
bladder stones, hematuria, and urinary retention), and an 
inability to speak and understand Korean. We also ex-
cluded individuals with a medical history of prostate or 
bladder surgery, pelvic radiotherapy, uncontrolled dia-
betes, dementia, any type of voiding dysfunction secondary 
to an underlying neurological disease, or any condition 
compromising mobility.
2. Medical therapy
The major aims of BPH treatment are relief of patient 
symptoms, improvement of QoL, and alteration of disease 
progression. Patients with mild symptoms (i.e., IPSS≤7) 
that are not extremely bothersome are considered candi-
dates for watchful waiting and were excluded from this 
study. In patients with moderate to severe (IPSS≥8) or 
bothersome symptoms, we prescribed α-blockers. We also 
administered 5-α-reductase inhibitors to patients whose 
prostate volume calculated by TRUS was greater than 30 
mL. Anticholinergics were not used before PVP in enrolled 
patients. Other medical treatments were similar to those 
of the European Association of Urology guidelines for BPH 
[5,6]. All enrolled patients received medications for more 
than 3 months before surgery. 
1) Urinary tract visualization
Cystoscopy (Olympus CYF-4 flexible cystoscope, 14 Fr; 
Olympus Europa Holding GmbH, Hamburg, Germany) 
was performed by one of two physicians (CDY and DHL, 
with 2 years of experience each) with the patient in the lith-
otomy position. Urethral and bladder structures were in-
spected conventionally except for the bladder neck, which 
was viewed in a retroflex position. We defined IPP as an 
intravesical protrusion of the prostate median lobe of more 
than 5 mm in diameter. The 14 Fr flexible cystoscope had 
a 4.7-mm diameter endoscope; therefore, we compared pro-
truding masses by using the endoscope. Patients were sub-
sequently assigned to either the IPP group or the no IPP 
group for comparison of surgical outcomes.
2) Operative technique
All men underwent PVP treatment under general or spinal 
anesthesia in accordance with surgeon and patient 
preferences. All patients received broad-spectrum anti-
biotics preoperatively and postoperatively. The perioper-
ative data collected included procedure duration, irriga-
tion volume, and length of hospital stay. During PVP, the 
total energy used, the number of fibers, and the eventual 
use of electrical coagulation or resection were also 
assessed. All patients were discharged after a PVR assess-
ment following catheter removal.
The PVP technique was performed by a surgeon (SHL) 
with 3 years of experience, and in most instances the proce-
dure required using only 60 W of power. The prostate later-
al lobes were vaporized bilaterally at first. After creating 
the working space from the bladder neck to the ver-
umontanum, the power setting was increased to 80 W, 100 
W, and finally 120 W to widen the cavity. The middle lobe, 
if present, was vaporized after completing the lateral lobe 
ablation. To control bleeding when it occurred, the coagu-
lation mode setting was used, wherein the power was re-
duced to 20 to 30 W and the laser beam was directed around, 
rather than directly at, the bleeding vessel. The fiber was 
introduced through a Karl Storz 23 Fr continuous flow 
cystoscope. Normal saline (0.9% sodium chloride solution) 
was used for irrigation. A 20 Fr three-way Foley catheter 
was inserted without irrigation in most cases.
3) Statistical analyses
Parametric numeric data (Fig. 1, comparison of IPP and no 
IPP groups at each follow-up period; Fig. 2, comparison of 
two groups at each period) were compared by using the 
t-test, and nonparametric data (Table 1, comparison of 
complications) were analyzed by using the Wilcoxon sign-
ed-rank test. A p-value＜0.05 was considered significant. 
Data were presented either as mean±standard deviation 
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FIG. 1. Changes in the total International Prostate Symptom 
Score (IPSS) score with time in the intravesical prostatic 
protrusion (IPP) and no IPP groups. a:Significant difference 
between the IPP and no IPP groups, p＜0.05. 
TABLE 1. Results of changes in IPSS and Qmax with time
Time
IPSS (total score) IPSS (voiding subscore) IPSS (storage subscore) IPSS (QoL) Qmax (mL/s)
IPP No IPP IPP No IPP IPP No IPP IPP No IPP IPP No IPP
Preop
1 mo
3 mo
6 mo　
22.4±7.0
12.8±7.8a
12.4±5.8a
14.9±5.7a
21.8±6.9
17.8±5.7a
14.7±5.4a
15.2±7.3a
14.8±4.1
  6.5±5.1a
  6.2±3.7a
  8.6±3.3a
13.4±4.5
10.5±4.0a
  8.3±4.1a
  9.4±4.7a
8.0±3.5
6.3±4.0
6.3±2.9a
6.2±2.8a
8.4±3.0
7.6±2.3
6.3±2.3a
5.8±3.0a
4.3±0.9
2.7±1.3a
2.1±1.0a
2.6±1.1a
3.9±0.8
3.6±1.3
2.9±1.2a
3.0±1.3a
10.6±3.8
14.9±4.8a
17.6±4.2a
18.9±4.2a
12.0±4.0
16.8±5.4a
17.2±3.9a
18.6±4.1a
Values are presented as mean±standard deviation.
IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; QoL, quality of life; IPP, intravesical prostatic protrusion; 
Preop, preoperative.
a:p＜0.05 compared with preoperative score.
FIG. 2. Changes in the voiding subscore with time in the 
intravesical prostatic protrusion (IPP) and no IPP groups. a: 
Significant difference between the IPP and no IPP groups, p
＜0.05.
or mean±standard deviation (range). To compare each fol-
low-up month’s data with the baseline data, the data were 
analyzed by using repeated-measures analysis of variance. 
Calculations were performed by using SAS ver. 9.1 (SAS 
Institute Inc, Cary, NC, USA).
RESULTS
The mean patient age was 66.6±7.8 years. The mean serum 
PSA level and prostate volume were 1.7±1.5 ng/mL and 
42.9±16.7 mL, respectively. There were no significant dif-
ferences between the IPP and no IPP groups in terms of pre-
operative characteristics such as prostate volume, total 
IPSS, and PSA levels. There were also no significant differ-
ences between these two patient groups in lasing time (IPP, 
29±14.3 months; no IPP, 24±15.4 months), lasing energy 
(IPP, 787±92.3 kJ; no IPP, 653±155 kJ), or hospital stay 
(IPP, 2.4±1.7 days; no IPP, 2.8±1.8 days; Table 2). The 
mean follow-up duration was 6.2±1.9 months.
After the operation, there were statistically significant 
differences compared with preoperative values in IPSS, 
Qmax, PVR, and QoL in both groups at the 1-, 3-, and 
6-month follow-ups. The IPP group showed significant im-
provements in total IPSS and voiding subscores at post-
operative months 1 and 3 (Table 1). However, improvement 
in the QoL score and storage subscore was not significantly 
different between the IPP and no IPP groups (Figs. 1–3). 
The Qmax was significantly improved at postoperative 
month 6 in the IPP group (+7.8 mL/s) compared with the 
no IPP group (+6.0 mL/s) (Fig. 4).
Operative complications and their frequencies are listed 
in Table 3. Intraoperative bleeding required electro-
cautery in nine IPP patients and three no IPP patients, and 
there was a similar trend for bleeding from the protruding 
median lobe in both patient groups. Postoperative gross 
hematuria presented in 16 (26%) IPP patients and in 10 
(14%) no IPP patients. Four of the 16 IPP patients required 
recatheterization for bladder irrigation, whereas 2 of the 
10 no IPP patients required recatheterization. However, 
the frequencies of all surgical complications were not sig-
nificantly different between the two patient groups.
DISCUSSION
When using flexible cystoscopy for visualization, the blad-
der should be moderately filled owing to the necessity for 
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TABLE 2. Baseline characteristics
        Characteristic IPP No IPP p-value
No. of patients
Age (y)
IPSS (total score)
Voiding subscore
Storage subscore
Quality of life
Prostate volume (mL)
Qmax (mL/s)
PVR (mL)
PSA (ng/mL)
62
  68.8±7.2 (54–86)
  22.4±7.0 (12–29)
14.8±4.1 (7–19)
  8.0±3.5 (2–10)
4.2±0.8 (3–6)
  45.9±19.2 (29–102)
10.6±3.8 (4–14)
59.0±43.3 (0–190)
        1.9±1.3 (0.18–9.4)
72
  65.7±8.2 (49–82)
  21.8±6.9 (12–24)
13.4±4.5 (4–18)
  8.4±3.0 (3–13)
3.9±0.7 (3–6)
40.3±13.8 (21–67)
12.0±4.0 (5–18)
43.7±31.0 (0–197)
        1.5±1.7 (0.11–7.9)
0.139
0.089
0.062
0.437
0.058
0.056
0.047
0.065
0.153
Values are presented as mean±standard deviation (range). 
IPP, intravesical prostatic protrusion; IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; PVR, postvoid re-
sidual; PSA, prostate-specific antigen.
FIG. 3. Changes in the storage subscore with time in the 
intravesical prostatic protrusion (IPP) and no IPP groups. 
FIG. 4. Improved maximal uroflow rate for up to 6 months after 
photoselective vaporization of the prostate. Qmax, maximum 
flow rate. a:Significant difference between the intravesical 
prostatic protrusion (IPP) and no IPP groups (t-test); p=0.821 at 
month 1, p=0.558 at month 3, p=0.047 at month 6.
TABLE 3. Perioperative and postoperative complications asso-
ciated with laser prostatectomy 
          Complication IPP No IPP p-value
Electrocautery hemostasis
Urinary tract infection 
Recatheterization 
Reoperation (TURP) 
Postoperative gross hematuria 
Transient incontinence 
Transient urgency 
Sustained urgency (＞6 mo)
  9 (14)
  6 (10)
  4 (7)
  3 (5)
16 (26)
  3 (5)
19 (31)
  3 (5)
  3 (4)
  8 (11)
  2 (3)
  0 (0)
10 (14)
  5 (7)
26 (36)
  3 (4)
0.093
0.792
0.101
0.123
0.892
0.234
0.976
0.799
Values are presented as number (%).
IPP, intravesical protatic protrusion; TURP, transurethral re-
section of the prostate.
sufficient space within which to bend the cystoscope. 
Therefore, we believe that IPP detection by cystoscopy is 
less influenced by the degree of bladder filling than is IPP 
evaluation via US [7]. We demonstrated here that PVP was 
an effective therapy for BPH patients with or without IPP. 
Improvement of the IPSS obstructive subscore was much 
higher in the IPP group than in the no IPP group during 
early (＜3 months) postoperative follow-up. However, the 
superiority of the improvement in the IPP group was not 
sustained at a relatively late period (postoperative month 
6). This might be because the elimination of a protruding 
mass in the bladder neck may have a greater effect on early 
improvement of voiding symptoms than the release of lu-
minal compression of the prostatic urethra. Therefore, pa-
tients with IPP experience early improvement because of 
the elimination of IPP. According to a long-term study [8], 
significant improvement of obstructive symptoms after 
PVP was shown at months 1 and 6. Relatively more symp-
toms of discomfort were noted in patients with IPP than in 
those without IPP. 
Despite the significantly lower preoperative Qmax in the 
IPP group, PVP resulted in marked improvement in both 
groups, with flow rates at the 6 months follow-up even 
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greater in the IPP group than in the no IPP group. This find-
ing might be due to delayed degradation of luminal com-
pressed tissue. However, this possibility should be con-
firmed with further large-scale controlled studies. 
Several studies have investigated the prevalence of IPP 
in BPH. Chia et al. [1] showed a positive correlation be-
tween IPP and BOO. They graded IPP in enrolled patients 
by using US and correlated these findings with urine pres-
sure flow studies. The results showed that a higher grade 
of IPP correlated with a higher BOO index. Keqin et al. [9] 
also reported that IPP was a useful predictor of BOO and 
of detrusor muscle function. Lee et al. [3] argued that a 
higher IPP grade is associated with a higher risk of clinical 
progression of BPH. In that retrospective analysis of 259 
men, IPP was graded as 1 (up to 5 mm protrusion), 2 (5 to 
10 mm), or 3 (greater than 10 mm). With the use of pre-
defined definitions of disease progression, including a dete-
rioration of four points on the IPSS or an increased PVR 
of greater than 100 mL, the odds ratio of disease pro-
gression of a grade 3 protrusion was significantly higher 
than that of a grade 2 protrusion. Mariappan et al. [10] re-
ported that a BPH trial without catheterization is more 
likely to fail in patients with an IPP larger than 10 mm.
Most prior studies, including those cited here, evaluated 
IPP by using abdominal US because of its noninvasive abil-
ity to identify intravesical anatomy. However, abdominal 
US has limited reliability in finding IPP and is highly oper-
ator-dependent. The degree of bladder filling also affects 
the accurate evaluation of IPP by use of US. Reliability is 
best when viewing a comfortably full bladder (-200 mL). 
When the bladder is overdistended (＞400 mL), the pros-
tate recedes below the pubic symphysis and is difficult to 
image correctly by US. In contrast, too little urine in the 
bladder (i.e., ＜100 mL) tends to result in overestimation 
of IPP [7]. Therefore, US findings tend to be subjective rath-
er than definitive because of the difficulty of standardizing 
US procedures and the variability in patient bladder 
status. 
Flexible cystoscopy is a reliable procedure for evaluation 
of the whole urethra and bladder at the same time. 
Although flexible cystoscopy is more invasive than US, 
some researchers have reported various methods for mini-
mizing patient pain during the procedure, such as viewing 
the monitor and increasing hydrostatic pressure (the “bag 
squeeze” technique) [11,12]. Abdominal US is a non-
invasive modality for the identification of vesical anatomy 
during optimal bladder filling. However, abdominal US 
cannot directly identify infravesical anatomical obstruc-
tions such as urethral obstruction or the degree of “kissing” 
of the prostate lateral lobes. Therefore, US can initially be 
useful in evaluating a patient with voiding difficulty, but 
this method is not ideal for following up patients who do 
not improve with optimal medical management for ob-
structive symptoms. 
The PVP procedure is an effective treatment modality to 
manage a moderately enlarged prostate. Alexis et al re-
ported that PVP was effective for long-term (12-month) im-
provement of obstruction secondary to BPH in 139 patients 
who had a mean prostate mass of 54.6 g [13]. Lukacs et al. 
[14] reported the superiority of PVP over transurethral re-
section of the prostate (TURP) in reducing the length of hos-
pital stay and in improving uroflowmetry parameters. 
Complication rates were comparable between PVP and 
TURP in this multicenter prospective trial. On the basis 
of their meta-analysis results, Zhang et al. [15] reported 
that PVP and TURP provide comparable functional im-
provements, including lowering the IPSS and increasing 
the Qmax, at the 6-, 12-, and 24 months follow-ups. Korean 
researchers have confirmed that PVP is an effective modal-
ity for removing obstructive prostate tissue, including a 
protruding median lobe [16]. 
Long-term medical therapy for BPH has shown good effi-
cacy and evidence of decreasing disease progression in sev-
eral studies, including the MTOPS, ALTESS, CombAT, 
and ALF-ONE trials. However, in real clinical practice, 
some BPH patients are unresponsive after several months 
of medical treatment and require reevaluation and in-
dividually tailored disease management [17,18]. There-
fore, to identify patients who require surgical correction for 
BPH, early evaluation of the status of the urethra and blad-
der by use of accurate and reliable diagnostic methods, 
such as flexible cystoscopy, is needed. Additionally, flexible 
cystoscopy is less invasive and causes less patient dis-
comfort than does conventional rigid cystoscopy. When ap-
propriate medical therapy over a period of months does not 
result in symptom improvement in BPH patients, we rec-
ommend flexible cystoscopy to confirm whether lateral lobe 
“kissing” or median lobe protrusion exists, which would be 
indications for surgical correction. 
A limitation of this study is that we did not investigate 
the effect of more than 3 months of sustained medical ther-
apy on BPH patients with IPP. To confirm the superiority 
of early intervention with flexible cystoscopy and PVP, 
comparative studies with extended medical therapy 
should be performed. 
CONCLUSIONS
The PVP procedure resulted in significant improvement in 
obstructive symptoms in BPH patients, regardless of 
whether IPP was present. We recommend that medically 
nonresponsive BPH patients be reevaluated by use of flexi-
ble cystoscopy to accurately identify the cause of an ob-
struction in the prostatic urethra.
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